Clinical Research Papers:
Therapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibody
Metrics: PDF 785 views | HTML 1049 views | ?
Gongcheng Wang1,*, Ziyu Wu2,*, Yunyan Wang1,*, Xueqin Li3, Guangbo Zhang4 and Jianquan Hou5
1 Department of Urology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China
2 Department of Urology, Huai’an Hospital Affiliated of Xuzhou Medical College and Huai’an Second People’s Hospital, Huai’an, Jiangsu, China
3 Department of Gerontology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China
4 Department of Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
* These authors have contributed equally to this work
Jianquan Hou, email:
Keywords: B7-H3; mice, nude; renal cell carcinoma; targeting therapy; monoclonal antibody
Received: July 19, 2015 Accepted: March 18, 2016 Published: April 02, 2016
B7-H3 is a tumor-associated antigen that plays a critical role in potential tumor-targeted therapy. In this study, we aimed to assess the radiobiological effect of 131I-labeled B7-H3 monoclonal antibody (131I-4H7) in nude mice with human renal cell carcinoma (RCC) and evaluate the effect of 131I-4H7 on RCC treatment. The radiobiological activity and tumor uptake of 131I-4H7, and its effect on tumor growth were measured. 131I-4H7 was absorbed by the tumor and reached its maximal uptake rate (3.32% injected dose [ID]/g) at 24 h, at which point the drug concentration in the tumor was 7.36-, 2.06-, 1.80-, and 2.78-fold higher than that in muscle, kidneys, liver, and heart, respectively. Measurements and positron emission tomography–computed tomography imaging showed that tumor development was significantly inhibited by 131I-4H7. HE staining revealed that 131I-4H7 significantly injures tumor cells. Our results suggest that 131I-4H7 is markedly absorbed by the tumor and did suppress the development of RCC xenografted tumors in nude mice, which might provide a new candidate for antibody-mediated targeted radiotherapy in human RCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.